Share-based Payment Arrangement, Expense of Verona Pharma plc from 31 Dec 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Verona Pharma plc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Jun 2025.
  • Verona Pharma plc Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $34,814,000, a 123% increase year-over-year.
  • Verona Pharma plc Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $93,683,000, a 218% increase year-over-year.
  • Verona Pharma plc annual Share-based Payment Arrangement, Expense for 2024 was $41,244,000, a 117% increase from 2023.
  • Verona Pharma plc annual Share-based Payment Arrangement, Expense for 2023 was $19,012,000, a 35% increase from 2022.
  • Verona Pharma plc annual Share-based Payment Arrangement, Expense for 2022 was $14,121,000, unchanged from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Verona Pharma plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $93,683,000 $34,814,000 +$19,220,000 +123% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $74,463,000 $37,477,000 +$33,219,000 +780% 01 Jan 2025 31 Mar 2025 10-Q 29 Apr 2025 2025 Q1
Q4 2024 $41,244,000 $13,738,000 +$9,169,000 +201% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $32,075,000 $7,654,000 +$2,575,000 +51% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2024 2024 Q3
Q2 2024 $29,500,000 $15,594,000 +$10,520,000 +207% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $18,980,000 $4,258,000 -$32,000 -0.75% 01 Jan 2024 31 Mar 2024 10-Q 29 Apr 2025 2025 Q1
Q4 2023 $19,012,000 $4,569,000 +$65,000 +1.4% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $18,947,000 $5,079,000 +$2,263,000 +80% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $16,684,000 $5,074,000 +$2,021,000 +66% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $14,663,000 $4,290,000 +$542,000 +14% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $14,121,000 $4,504,000 +$11,622,000 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $2,499,000 $2,816,000 -$2,122,000 -43% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $4,621,000 $3,053,000 -$4,398,000 -59% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $9,019,000 $3,748,000 -$5,102,000 -58% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $14,121,000 $7,118,000 -$19,992,000 -155% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2025 2024 FY
Q3 2021 $34,113,000 $4,938,000 -$1,548,000 -24% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $35,661,000 $7,451,000 +$6,501,000 +684% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $29,160,000 $8,850,000 +$6,983,000 +374% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $22,177,000 $12,874,000 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q3 2020 $6,486,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $950,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $1,867,000 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1

Verona Pharma plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $41,244,000 +$22,232,000 +117% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $19,012,000 +$4,891,000 +35% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $14,121,000 $0 0% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $14,121,000 -$8,056,000 -36% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2025 2024 FY
2020 $22,177,000 +$19,058,000 +611% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
2019 $3,119,000 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.